Fluciclovine PET/CT Improves Targeted Radiation Treatment of Recurrent Prostate Cancer

Share this content:
F-18-fluciclovine PET helps detect and localize recurrent prostate cancer allowing for individualized, targeted therapy.
F-18-fluciclovine PET helps detect and localize recurrent prostate cancer allowing for individualized, targeted therapy.

The positron emission tomography (PET) radiotracer fluciclovine (fluorine-18; F-18) can be used to monitor and guide treatment of patients with recurrent prostate cancer.1

"This is the first study of its kind demonstrating changes in postsurgery radiotherapy target design with advanced molecular imaging in recurrent prostate cancer, with no demonstrated increase in early radiotherapy side effects," explains Ashesh B. Jani, MD, of the Winship Cancer Institute of Emory University, and lead researcher of a recent study published in the Journal of Nuclear Medicine.

The clinical trial included 96 patients with recurrent prostate cancer after prostatectomy. All patients received initial treatment planning using conventional abdominopelvic imaging (CT or MRI). Forty-five patients underwent an additional abdominopelvic F-18-fluciclovine PET/CT, which better defined the tumor target area leading to modification of the previous treatment plan.

The inclusion of F-18-fluciclovine PET information in treatment planning led to significant differences in the areas to receive radiotherapy. Higher doses were observed in the penile bulb, but no significant differences in bladder or rectal radiation or in acute genitourinary or gastrointestinal toxicity were observed.

This is the first set of results from a 3-year long study, where investigators expect to observe an increase in disease-free survival for patients who received F-18-fluciclovine PET with subsequent treatment modification, compared with those who did not receive treatment modification informed by F-18-fluciclovine PET.

F-18-fluciclovine PET helps doctors to detect and localize prostate cancer allowing for individualized, targeted therapy and could have broader implications. According to Jani, "Our methodology is readily applicable to other novel imaging agents, and it may potentially facilitate improvement of cancer control outcomes."


1. Jani AB, Schreibmann E, Rossi PJ, et al. Impact of 18F-fluciclovine PET on target volume definition for postprostatectomy salvage radiotherapy: initial findings from a randomized trial. J Nucl Med. 2017;58(3):412-418. doi: 10.2967/jnumed.116.176057
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs